Related references
Note: Only part of the references are listed.LESINURAD, A SELECTIVE URIC ACID REABSORPTION INHIBITOR, IN COMBINATION WITH ALLOPURINOL: RESULTS FROM A PHASE III STUDY IN GOUT PATIENTS HAVING AN INADEQUATE RESPONSE TO STANDARD OF CARE (CLEAR 1)
K. Saag et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
LESINURAD, A SELECTIVE URIC ACID REABSORPTION INHIBITOR, IN COMBINATION WITH ALLOPURINOL: RESULTS FROM A PHASE III STUDY IN GOUT PATIENTS HAVING AN INADEQUATE RESPONSE TO STANDARD OF CARE (CLEAR 2)
T. Bardin et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
LESINURAD MONOTHERAPY IN GOUT PATIENTS INTOLERANT TO XANTHINE OXIDASE INHIBITORS (LIGHT): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 6-MONTH PHASE III CLINICAL TRIAL
A. -K. Tausche et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
LESINURAD, A NOVEL SELECTIVE URIC ACID REABSORPTION INHIBITOR, IN COMBINATION WITH FEBUXOSTAT, IN PATIENTS WITH TOPHACEOUS GOUT: THE CRYSTAL PHASE III CLINICAL TRIAL
N. Dalbeth et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
RELATIONSHIP BETWEEN SUSTAINED LOWERING OF SERUM URATE LEVELS AND IMPROVEMENTS IN GOUT FLARES AND TOPHUS AREA: POOLED EXPLORATORY ANALYSIS OF GOUT SUBJECTS RECEIVING LESINURAD AND XANTHINE OXIDASE INHIBITOR COMBINATION THERAPY
R. Terkeltaub et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Allopurinol use and risk of non-fatal acute myocardial infarction
Francisco J. de Abajo et al.
HEART (2015)
Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis
Tahir Kanji et al.
BMC NEPHROLOGY (2015)
Impact of allopurinol on risk of myocardial infarction
L. Grimaldi-Bensouda et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Investigation of pegloticase-associated adverse events from a nationwide reporting system database
William Gentry et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2014)
Cost-Effectiveness of Allopurinol and Febuxostat for the Management of Gout
Eric Jutkowitz et al.
ANNALS OF INTERNAL MEDICINE (2014)
SAT0356 The Therapeutic Efficacy of the Novel Uricosuric Agent UR-1102 for Hyperuricemia and Gout
S. O. Ahn et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
NOVEL BIFUNCTIONAL INHIBITORS OF XANTHINE OXIDASE AND URAT1 INDUCE PROFOUND HYPOURICEMIA IN HUMAN SUBJECTS
R. P. Warrell et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout
Tatsuo Hosoya et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2014)
Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy
Herbert S. B. Baraf et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2014)
Oxypurinol Directly and Immediately Activates the Drug-Specific T Cells via the Preferential Use of HLA-B*58:01
James Yun et al.
JOURNAL OF IMMUNOLOGY (2014)
Allopurinol use in a New Zealand population: prevalence and adherence
Simon Horsburgh et al.
RHEUMATOLOGY INTERNATIONAL (2014)
Impaired response or insufficient dosage?-Examining the potential causes of inadequate response to allopurinol in the treatment of gout
Lisa K. Stamp et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2014)
Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients
Michael S. Hershfield et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
Peter E. Lipsky et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia
Thomas M. MacDonald et al.
BMJ OPEN (2014)
Cost-effectiveness of febuxostat in chronic gout
Stephen M. Beard et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2014)
Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study
Frances Rees et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
RDEA3170, A NOVEL, HIGH AFFINITY URAT1 INHIBITOR BINDS TO A CENTRAL DOMAIN WITHIN URAT1
J. N. Miner et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
LONG-TERM SAFETY OF BCX4208 ADDED TO ALLOPURINOL IN THE CHRONIC MANAGEMENT OF GOUT: RESULTS OF A PHASE 2 24-WEEK BLINDED SAFETY EXTENSION AND VACCINE CHALLENGE STUDY
A. S. Hollister et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
BCX4208, A NOVEL ENZYME INHIBITOR FOR CHRONIC MANAGEMENT OF GOUT, SHOWS A LOW RISK OF POTENTIAL DRUG-DRUG INTERACTIONS
S. Bantia et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
BCX4208 ADDED TO ALLOPURINOL INCREASES RESPONSE RATES IN PATIENTS WITH GOUT WHO FAIL TO REACH GOAL RANGE SERUM URIC ACID ON ALLOPURINOL ALONE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
M. A. Becker et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Clinical Risk Factors for Adverse Events in Allopurinol Users
Hee Jung Ryu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Efficacy and Tolerability of Probenecid as Urate-lowering Therapy in Gout; Clinical Experience in High-prevalence Population
Karen Pui et al.
JOURNAL OF RHEUMATOLOGY (2013)
Gout-Related Health Care Utilization in US Emergency Departments, 2006 Through 2008
Rohini Garg et al.
ARTHRITIS CARE & RESEARCH (2013)
Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
Herbert S. B. Baraf et al.
ARTHRITIS RESEARCH & THERAPY (2013)
CArdiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular ComoRbiditiES
William B. White et al.
AMERICAN HEART JOURNAL (2012)
Patient and provider barriers to effective management of gout in general practice: a qualitative study
Karen Spencer et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Gout: why is this curable disease so seldom cured?
Michael Doherty et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Reversal of serologic, immunologic, and histologic dysfunction in mice with systemic lupus erythematosus by long-term serial adipose tissue-derived mesenchymal stem cell transplantation
Eun Wha Choi et al.
ARTHRITIS AND RHEUMATISM (2012)
Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol
Lisa K. Stamp et al.
ARTHRITIS AND RHEUMATISM (2012)
2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia
Dinesh Khanna et al.
ARTHRITIS CARE & RESEARCH (2012)
Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma
Robyn T. Domsic et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Reduction of In Vitro Invasion and In Vivo Cartilage Degradation in a SCID Mouse Model by Loss of Function of the Fibrinolytic System of Rheumatoid Arthritis Synovial Fibroblasts
Simona Serrati et al.
ARTHRITIS AND RHEUMATISM (2011)
Using Allopurinol Above the Dose Based on Creatinine Clearance Is Effective and Safe in Patients With Chronic Gout, Including Those With Renal Impairment
Lisa K. Stamp et al.
ARTHRITIS AND RHEUMATISM (2011)
Prevalence of Gout and Hyperuricemia in the US General Population The National Health and Nutrition Examination Survey 2007-2008
Yanyan Zhu et al.
ARTHRITIS AND RHEUMATISM (2011)
Efficacy and Tolerability of Pegloticase for the Treatment of Chronic Gout in Patients Refractory to Conventional Treatment
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
JAPANESE GUIDELINE FOR THE MANAGEMENT OF HYPERURICEMIA AND GOUT: SECOND EDITION
Hisashi Yamanaka
NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS (2011)
Hyperuricemia and Incident Hypertension: A Systematic Review and Meta-Analysis
Peter C. Grayson et al.
ARTHRITIS CARE & RESEARCH (2011)
Contemporary epidemiology of gout in the UK general population
Lucia Cea Soriano et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Evidence That Dkk-1 Is Dysfunctional in Ankylosing Spondylitis
Dimitrios Daoussis et al.
ARTHRITIS AND RHEUMATISM (2010)
The urate-lowering Efficacy and Safety of Febuxostat in the Treatment Hyperuricemia of Gout: The CONFIRMS trial
C. Dejaco et al.
JOURNAL FUR MINERALSTOFFWECHSEL (2010)
The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: the CONFIRMS trial
Michael A. Becker et al.
ARTHRITIS RESEARCH & THERAPY (2010)
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout
M. K. Reinders et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Hyperuricemia and Risk of Stroke: A Systematic Review and Meta-Analysis
Seo Young Kim et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2009)
Factors Associated With Recurrent Hospital Admissions for Gout A Case-Control Study
Ingrid Hutton et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2009)
Quality of Life and Disability in Patients with Treatment-Failure Gout
Michael A. Becker et al.
JOURNAL OF RHEUMATOLOGY (2009)
Effects of Febuxostat Versus Allopurinol and Placebo in Reducing Serum Urate in Subjects With Hyperuricemia and Gout: A 28-Week, Phase III, Randomized, Double-Blind, Parallel-Group Trial
H. Ralph Schumacher et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2008)
A benefit-risk assessment of benzbromarone in the treatment of gout - Was its withdrawal from the market in the best interest of patients?
Ming-Han H. Lee et al.
DRUG SAFETY (2008)
Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension - A randomized trial
Daniel I. Feig et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans
J. A. Singh et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Estimates of the prevalence of arthritis and other rheumatic conditions in the United States
Reva C. Lawrence et al.
ARTHRITIS AND RHEUMATISM (2008)
Biochemical effectiveness of allopurinol and allopurinol-probenecid in previously benzbromarone-treated gout patients
Mattheus K. Reinders et al.
CLINICAL RHEUMATOLOGY (2007)
British Society for Rheumatology and British Health Professionals in rheumatology guideline for the management of gout
Kelsey M. Jordan et al.
RHEUMATOLOGY (2007)
EULAR evidence based recommendations for gout.: Part II:: Management.: Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT)
W. Zhang et al.
ANNALS OF THE RHEUMATIC DISEASES (2006)
Febuxostat compared with allopurinol in patients with hyperuricemia and gout
MA Becker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Pathogenesis of gout
HK Choi et al.
ANNALS OF INTERNAL MEDICINE (2005)
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol
SL Hung et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Febuxostat, a Novel Nonpurine Selective Inhibitor of Xanthine Oxidase
Michael A. Becker et al.
ARTHRITIS AND RHEUMATISM (2005)
Share Paper
